Coronary stent restenosis in patients treated with cilostazol - Wikidata - wikimedia - TriplyDB

Coronary stent restenosis in patients treated with cilostazol

Coronary stent restenosis in patients treated with cilostazol

http://www.wikidata.org/entity/Q28192871

about

An unusual case of acute respiratory failure in a patient with pulmonary veins stenosis late after catheter ablation of atrial fibrillation: a case report and the review of the literature Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials Antiplatelet therapy for carotid artery stenting The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model Effect of pioglitazone on in-stent restenosis after coronary drug-eluting stent implantation: a meta-analysis of randomized controlled trials Clopidogrel desensitization: case report and review of published protocols.Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.Open-Label Phase I Clinical Study to Assess the Safety and Efficacy of Cilostazol in Patients Undergoing Internal Carotid Artery Stent Placement Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischem Advances in targeting cyclic nucleotide phosphodiesterases Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia.Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials.Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy.The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine.Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy Ac Age, male gender, and atrial fibrillation predict lower extremity amputation or revascularization in patients with peripheral artery diseases: a population-based investigation.A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.Restenosis related to percutaneous coronary intervention has been solved?Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients Coping with new challenges in acute coronary syndromes.Cypher versus Taxus: the stent war.Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?Efficacy of triple anti-platelet therapy including cilostazol in acute myocardial infarction patients undergoing drug-eluting stent implantation.Safety and efficacy of cilostazol in the management of intermittent claudication.Update on oral antiplatelet therapy: principles, problems and promises.Negative Association of Circulating MicroRNA-126 with High-sensitive C-reactive Protein and Vascular Cell Adhesion Molecule-1 in Patients with Coronary Artery Disease Following Percutaneous Coronary Intervention.Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis.Pharmacological prevention and management of restenosis.Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?Antiplatelet therapy and vascular disease: an update.Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention.

P2860

Q26779375-C3589A22-3355-4E73-9C32-C72D991D4177 Q26785723-21062DBD-5A9E-42A1-B8EB-E621A3720C99 Q26852304-A3776725-22DB-4684-8295-63AA511EDF9F Q28080657-ADFA816B-35D9-4EEB-9D21-2470502C596B Q28477044-94C3A5D1-688B-4252-AC4C-A153AD4914B7 Q28543544-6BA6596B-7215-4182-AA0F-8BAE301994D7 Q33378440-6671D419-AE05-4CA3-9BF9-B7F9BA5339D2 Q33390176-CB410816-E580-4F96-A588-EB7E12B3A191 Q33781981-5A72B8B0-6035-47BA-B275-A92596C5CDC7 Q34114530-981D6C58-258C-476D-BBAF-F6D0FD547B50 Q34139490-520E5210-192F-4795-B624-81F301C34E61 Q34381782-409972A7-BD2C-45F6-8789-7397C125A4B0 Q34521985-CAF22656-A2FD-48A4-9991-1741162ABBA2 Q34524341-94A46C40-9596-4869-AEFB-B0EB1A5AE5A4 Q34755672-EF1EDCA9-1B3F-496E-BB61-0CC0D5904040 Q35740400-6CA5C7B1-F2FC-4E67-A427-98DEEB4AB44F Q35993782-91C03BAB-3691-4F2B-BEB1-F4DE98BB8157 Q36036395-7A2FE07A-431D-439D-B7CC-5EF36AE780B9 Q36238939-1FEECCE5-BD70-4FD5-B2F2-F7F03B8AD013 Q36374457-41932C80-2E9A-4E24-889C-F42B89B25A17 Q36486769-C237561B-2485-425A-8B17-B7814A327776 Q36503391-A4663A95-3C65-42F2-B076-4A6E9359CA57 Q36575461-3F2D0AF9-4CFE-4FB0-A6C1-9E8E9C6221B7 Q36654328-1834EC11-BB73-4C15-9AF9-3123E6E513C0 Q36736604-34A8EBBB-89EE-4243-8D76-7B3B7AA7BF15 Q37164669-F2D5CCDF-82D3-492B-8EA8-0D739FFF038D Q37321394-21854C44-2CAE-4D3A-B1FE-A7D53BA5CB9D Q37362773-C242DC0A-52FF-4BB1-8D07-AD7186085BC9 Q37408663-0016C4A6-C79F-4AAB-9A30-3875826FCB55 Q37428855-A1841689-441F-42EA-8EEC-FF238AE7B94E Q37486605-0DD02BD5-C307-4525-B80E-D9D12488C37C Q37487606-BB47211A-4AED-4AA0-9B3D-3359E1EF57C8 Q37588002-072F7116-31F5-490A-8688-30D4C41581AF Q37676766-5D10CCDD-788D-4E86-9804-AFC5ABDAB30B Q37756979-AAE3920E-447C-4B15-B6A7-C6A8D3E7D4F8 Q37797795-7D98FE5A-BFAB-471E-A9A2-9FD611FCE286 Q37827882-C91AA06F-EFEE-4EDC-B132-B8AB927CB2B7 Q37834033-A1A59876-64DD-41F6-BC5E-2391B28C7862 Q37838100-214456C4-0CF1-467F-9136-00C1A7EE38A8 Q37841560-FD549FE7-005F-4973-A914-837610E8CF41

P2860

Coronary stent restenosis in patients treated with cilostazol

http://www.wikidata.org/entity/Q28192871

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Coronary stent restenosis in patients treated with cilostazol

@ast

Coronary stent restenosis in patients treated with cilostazol

@en

Coronary stent restenosis in patients treated with cilostazol

@nl

type

label

Coronary stent restenosis in patients treated with cilostazol

@ast

Coronary stent restenosis in patients treated with cilostazol

@en

Coronary stent restenosis in patients treated with cilostazol

@nl

prefLabel

Coronary stent restenosis in patients treated with cilostazol

@ast

Coronary stent restenosis in patients treated with cilostazol

@en

Coronary stent restenosis in patients treated with cilostazol

@nl

P1433

Q28192871-B51A7919-F422-4A73-AF1B-1DF272EB732B

P1476

Q28192871-734FD649-0E76-4D6A-A9A1-B88FE2D0A134

P2093

Q28192871-0673C854-F066-44EB-8759-B16153B022F4

Q28192871-0A2011EA-6FE5-451C-9EB3-8E3F31A5504B

Q28192871-29F2E8B2-916A-49A3-B155-C024F5BDADBF

Q28192871-30957A39-27C8-44D7-89C1-930C754C9628

Q28192871-36D79B03-0A2C-4BC2-98AD-D3C37FEF9132

Q28192871-3D4A82F5-386F-4501-813F-CB7FDC980D10

Q28192871-40D59CE0-9227-456B-A09D-556B4BECEC24

Q28192871-5D96D16D-D507-464F-B92C-48D516158F48

Q28192871-642FF62E-2599-45EB-8785-70742D830343

Q28192871-A5C4686A-2A00-4D6B-A15D-ABA11BAF0CB2

P304

Q28192871-3DF42764-0159-4A29-8579-3032C9F7C276

P31

Q28192871-E07C25EB-A9D1-4D81-BAC8-DA5D578F956B

P356

Q28192871-4AA070F3-40BE-48AA-A50C-29AC7E2D821A

P407

Q28192871-A0B641C6-83E5-4E10-880A-F32EC5D4E3AD

P433

Q28192871-F3CEAB24-8375-4644-AD97-27C395724822

P478

Q28192871-50A0C67D-173F-4640-AD12-3E27354A4ED7

P577

Q28192871-49D8C0BE-22D0-4CB3-8D2E-17BCC5E4DE3A

P698

Q28192871-A657A115-F4F2-4DDA-8186-BD578D850D89

P356

CIRCULATIONAHA.104.530097

P1433

P1476

Coronary stent restenosis in patients treated with cilostazol

@en

P2093

Cindy L Grines

http://www.w3.org/2001/XMLSchema#string

Claudine Jurkovitz

http://www.w3.org/2001/XMLSchema#string

David R Holmes

http://www.w3.org/2001/XMLSchema#string

Dean J Kereiakes

http://www.w3.org/2001/XMLSchema#string

Douglas C Morris

http://www.w3.org/2001/XMLSchema#string

Elizabeth Block

http://www.w3.org/2001/XMLSchema#string

G B John Mancini

http://www.w3.org/2001/XMLSchema#string

Henry Liberman

http://www.w3.org/2001/XMLSchema#string

John S Douglas

http://www.w3.org/2001/XMLSchema#string

Jovonne Foster

http://www.w3.org/2001/XMLSchema#string

P304

2826-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.104.530097

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16246948

http://www.w3.org/2001/XMLSchema#string